EQRx Shifts Strategy Amid FDA Feedback on China-Sourced Data
US-based EQRx Inc. (Nasdaq: EQRX), a biopharma originally established with the aim of “radically” disrupting...
PD-1/L1
CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study
China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...
Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma
China-based Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the enrollment of the first patient...
Akeso Biopharma Completes Enrollment for AK112 Phase III Study
China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...
Eli Lilly’s Peresolimab and LOXO-783 Gain Tacit Clinical Trial Approvals in China
The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approvals to...
Shandong Buchang Partners with REMD Bio for Bispecific Antibody Development
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced a co-development and licensing agreement...
NMPA Grants Second Approval to Henlius’ Serplulimab for Lung Cancer
The National Medical Products Administration (NMPA) has granted a second marketing approval to HaiSiZhuang (serplulimab),...
Junshi Biosciences Reports 55% Drop in Q3 Revenues
Shanghai-based biotech Junshi Biosciences (HKG: 1877) released its financial report for the third quarter of...
Innovent’s Tyvyt Approved for New Gastric Cancer Indication by NMPA
China-based Innovent Biologics, Inc. (HKG: 1801) and its partner Eli Lilly & Co. (NYSE: LLY)...
HutchMed Initiates Phase II/III Study for Elunate and Tyvyt in Renal Cell Carcinoma
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase...
Simcere Receives FDA Clearance for Clinical Study of SIM0237
China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the US...
Shanghai Henlius’ PD-1 Inhibitor Serplulimab Gains Australian Clearance for Phase III Study
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced receiving regulatory clearance in Australia to...
Hengrui Medicine Gains Approval for Phase Ib/II Study of SHR-A1811 and SHR-1701 in HER2-Positive Gastric Cancer
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval to initiate a...
Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China
The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd’s...
Akeso Biopharma Gains NMPA Approval for AK112 and AK119 Clinical Study
China-based Akeso Biopharma (HKG: 9926) has announced receiving approval from the National Medical Products Administration...
Hengrui Medicine’s Deputy GM Tao Weikang Resigns, Joins Qilu Pharma
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its deputy general manager...
BeiGene Partners with Immune-Onc for Clinical Development of Myeloid Checkpoint Inhibitors
China-based biotech BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a clinical study...
Merck’s Keytruda Gains 9th Indication Approval in China for Hepatocellular Carcinoma
US major Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab)...